Alpha 1-antitrypsin-deficiency-related emphysema.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: A congenital cause of emphysema resulting from alpha 1-antitrypsin (A1AT) deficiency affects 1 in 2500 individuals and could account for emphysema in 2 percent of all persons with emphysema. Individuals aged 30 to 45 years with chronic shortness of breath and coughing could have A1AT deficiency. METHODS: Using the key words "alpha 1-antitrypsin deficiency," "chronic obstructive pulmonary disease," and "emphysema," the MEDLINE files were searched from 1985 to the present. Data from articles published before 1985 were accessed from cross-reference of the recent articles. RESULTS AND CONCLUSIONS: Unlike smoker's emphysema, A1AT deficiency is panacinar, appears in middle-aged patients, and is more severe at the lung bases. Chronic bronchitis, mucous hypersecretion, and liver disease, as well as a family history of emphysema, are associated conditions. Clinical management includes the avoidance of smoking and atmospheric pollution. Also available is purified, functional human A1AT in quantities large enough for intravenous replacement or augmentation therapy. Future treatment for the disease includes synthetic elastase inhibitors and an aerosolized formulation of A1AT, which is currently under investigation.

Original languageEnglish (US)
Pages (from-to)489-493
Number of pages5
JournalThe Journal of the American Board of Family Practice / American Board of Family Practice
Volume5
Issue number5
StatePublished - Sep 1992

Fingerprint

alpha 1-Antitrypsin Deficiency
Emphysema
alpha 1-Antitrypsin
Pulmonary Emphysema
Pancreatic Elastase
Chronic Bronchitis
MEDLINE
Dyspnea
Chronic Obstructive Pulmonary Disease
Liver Diseases
Smoking
Autosomal Recessive alpha-1-Antitrypsin Deficiency
Lung
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{afbad9e900164cc7a705d555fb46e84b,
title = "Alpha 1-antitrypsin-deficiency-related emphysema.",
abstract = "BACKGROUND: A congenital cause of emphysema resulting from alpha 1-antitrypsin (A1AT) deficiency affects 1 in 2500 individuals and could account for emphysema in 2 percent of all persons with emphysema. Individuals aged 30 to 45 years with chronic shortness of breath and coughing could have A1AT deficiency. METHODS: Using the key words {"}alpha 1-antitrypsin deficiency,{"} {"}chronic obstructive pulmonary disease,{"} and {"}emphysema,{"} the MEDLINE files were searched from 1985 to the present. Data from articles published before 1985 were accessed from cross-reference of the recent articles. RESULTS AND CONCLUSIONS: Unlike smoker's emphysema, A1AT deficiency is panacinar, appears in middle-aged patients, and is more severe at the lung bases. Chronic bronchitis, mucous hypersecretion, and liver disease, as well as a family history of emphysema, are associated conditions. Clinical management includes the avoidance of smoking and atmospheric pollution. Also available is purified, functional human A1AT in quantities large enough for intravenous replacement or augmentation therapy. Future treatment for the disease includes synthetic elastase inhibitors and an aerosolized formulation of A1AT, which is currently under investigation.",
author = "Alan Barker",
year = "1992",
month = "9",
language = "English (US)",
volume = "5",
pages = "489--493",
journal = "Journal of the American Board of Family Medicine",
issn = "1557-2625",
publisher = "American Board of Family Medicine",
number = "5",

}

TY - JOUR

T1 - Alpha 1-antitrypsin-deficiency-related emphysema.

AU - Barker, Alan

PY - 1992/9

Y1 - 1992/9

N2 - BACKGROUND: A congenital cause of emphysema resulting from alpha 1-antitrypsin (A1AT) deficiency affects 1 in 2500 individuals and could account for emphysema in 2 percent of all persons with emphysema. Individuals aged 30 to 45 years with chronic shortness of breath and coughing could have A1AT deficiency. METHODS: Using the key words "alpha 1-antitrypsin deficiency," "chronic obstructive pulmonary disease," and "emphysema," the MEDLINE files were searched from 1985 to the present. Data from articles published before 1985 were accessed from cross-reference of the recent articles. RESULTS AND CONCLUSIONS: Unlike smoker's emphysema, A1AT deficiency is panacinar, appears in middle-aged patients, and is more severe at the lung bases. Chronic bronchitis, mucous hypersecretion, and liver disease, as well as a family history of emphysema, are associated conditions. Clinical management includes the avoidance of smoking and atmospheric pollution. Also available is purified, functional human A1AT in quantities large enough for intravenous replacement or augmentation therapy. Future treatment for the disease includes synthetic elastase inhibitors and an aerosolized formulation of A1AT, which is currently under investigation.

AB - BACKGROUND: A congenital cause of emphysema resulting from alpha 1-antitrypsin (A1AT) deficiency affects 1 in 2500 individuals and could account for emphysema in 2 percent of all persons with emphysema. Individuals aged 30 to 45 years with chronic shortness of breath and coughing could have A1AT deficiency. METHODS: Using the key words "alpha 1-antitrypsin deficiency," "chronic obstructive pulmonary disease," and "emphysema," the MEDLINE files were searched from 1985 to the present. Data from articles published before 1985 were accessed from cross-reference of the recent articles. RESULTS AND CONCLUSIONS: Unlike smoker's emphysema, A1AT deficiency is panacinar, appears in middle-aged patients, and is more severe at the lung bases. Chronic bronchitis, mucous hypersecretion, and liver disease, as well as a family history of emphysema, are associated conditions. Clinical management includes the avoidance of smoking and atmospheric pollution. Also available is purified, functional human A1AT in quantities large enough for intravenous replacement or augmentation therapy. Future treatment for the disease includes synthetic elastase inhibitors and an aerosolized formulation of A1AT, which is currently under investigation.

UR - http://www.scopus.com/inward/record.url?scp=0026926198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026926198&partnerID=8YFLogxK

M3 - Article

C2 - 1414450

AN - SCOPUS:0026926198

VL - 5

SP - 489

EP - 493

JO - Journal of the American Board of Family Medicine

JF - Journal of the American Board of Family Medicine

SN - 1557-2625

IS - 5

ER -